Malaria findings hold 'great promise' in vax R&D, team says


In a study that could provide a needed boost for malaria vaccine research, a team in Australia has blocked P. falciparum parasites from infecting human red blood cells by targeting three proteins found to be necessary for infection.

Led by professor Alan Cowman, the group at Walter and Eliza Hall Institute targeted and deleted the proteins Rh5, Ripr and CyRPA and in turn blocked malarial infection. According to the researchers, the proteins form a complex that is “essential in the sequential molecular events leading to parasite invasion.”

Published in Cell Host & Microbe, the new findings “hold great promise for understanding the function of these proteins and their development as vaccines,” Cowman said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While in early stages, the work could provide a new direction for vaccine researchers in the field and comes as GlaxoSmithKline seeks to roll out its first-gen malaria vaccine Mosquirix. Seen as far from perfect, GSK’s jab offers 39% efficacy that fades over time. Last week a study found that the vaccine’s effectiveness fades to nearly 0% in children after 7 years, information that could shape future immunization strategies.

But before any such large-scale campaigns, Mosquirix will need to undergo small pilot programs that will test its real-world efficacy. Following its EMA approval last July, the WHO ordered local studies that will further test the shot. Last month, Gavi stepped up to offer $27.5 million in funding for the programs if its contribution is matched.

New malaria research is needed, the Walter and Eliza Hall Institute team said, because parasites have adapted to existing treatments, creating a desperate need for next-gen approaches. Two hundred million people worldwide contract malaria each year, while the disease leaves up to 450,000 dead annually, mostly children under 5.

- here’s the release
- and the abstract

Related Articles:
Gavi floats $27.5M for pilot studies of GSK's Mosquirix
Experts call for more vaccine implementation testing
GSK's malaria vaccine hits roadblock as WHO recommends pilot projects
Glaxo's malaria vaccine gets EMA green light


Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.